切换至 "中华医学电子期刊资源库"

中华胃肠内镜电子杂志 ›› 2019, Vol. 06 ›› Issue (03) : 121 -124. doi: 10.3877/cma.j.issn.2095-7157.2019.03.006

所属专题: 专题评论 文献

综述

进展期结直肠癌新辅助治疗疗效评价方法的研究进展
詹红丽1, 王蓉1, 王雯1,()   
  1. 1. 350025 福建 福州,联勤保障部队第九〇〇医院消化内科,福建医科大学福总临床医学院,厦门大学附属东方医院
  • 收稿日期:2019-08-02 出版日期:2019-08-15
  • 通信作者: 王雯
  • 基金资助:
    福建省社会发展引导性(重点)项目(2018Y0066)

Advances in study on evaluation methods of neoadjuvant therapy for advanced colorectal cancer

Hongli Zhan1, Rong Wang1, Wen Wang1,()   

  1. 1. Department of Gastroenterology, 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Eastern Hospital Affiliated to Xiamen University, Fuzhou 350025, China
  • Received:2019-08-02 Published:2019-08-15
  • Corresponding author: Wen Wang
  • About author:
    Corresponding author: Wang Wen, Email:
引用本文:

詹红丽, 王蓉, 王雯. 进展期结直肠癌新辅助治疗疗效评价方法的研究进展[J/OL]. 中华胃肠内镜电子杂志, 2019, 06(03): 121-124.

Hongli Zhan, Rong Wang, Wen Wang. Advances in study on evaluation methods of neoadjuvant therapy for advanced colorectal cancer[J/OL]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2019, 06(03): 121-124.

新辅助治疗可使原发肿瘤或转移病灶缩小,降低肿瘤分期,已被认为是进展期结直肠癌(ACRC)的主要治疗方式。但由于肠道为空腔脏器,原发病灶准确测量困难,新辅助治疗后的疗效评估更加困难。因此,就结直肠癌而言,目前缺乏统一的、有针对性的、效果明显的评价系统和标准。本文就ACRC新辅助治疗目前疗效评价方法做一综述。

The primary or metastatic tumor, even the tumor stage may be reduced after neoadjuvant therapy, and it has been considered as the main treatment for advanced colorectal cancer(ACRC). However, the accurate measurement of the primary lesion in hollow organ, such as the intestine, is difficult, so as the evaluation of the therapeutic effect after neoadjuvant therapy.Therefore, there is no unified, targeted, and effective evaluation systems and standards for colorectal cancer, and this article reviews the current efficacy evaluation methods of ACRC neoadjuvant therapy.

[1]
Wong PK, Berry S, Spithorff K,et al.Preoperative or postoperative therapy for stageⅡrectal cancer:updated practice guideline[J].Clin Oncol(R Coil Radial),2010,22(4): 265-271.
[2]
Rolf Sauer, Heinz Becker, Werner Hohenberger,et al.Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer[J].N Engl J Med, 2004,351: 1731-1740.
[3]
Sun Z, Adam MA, Kim J,et al.Association Between Neoadjuvant Chemoradiation and Survival for Patients With Locally Advanced Rectal Cancer[J].Colorectal Dis, 2017, 19(12): 1058-1066.
[4]
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology [J].J Natl Compr Canc Netw,2018,16(7): 874-901.
[5]
Martin EW, Minton JP, Carey LC.CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma[J].Ann Surg,1985,202(3): 310-317.
[6]
Nicholson BD, Shinkins B, Pathiraja I,et al.Blood CEA levels for detecting recurrent colorectal cancer[J]. Cochrane Database Syst Rev,2015,10(12): CD011134.
[7]
彭俊杰,朱骥,刘方奇,等.中国局部进展期直肠癌诊疗专家共识[J].中国癌症杂志,2017,27(1): 41-80.
[8]
Bipat S, Glas AS, Slors FJ,et al.Rectal cancer:local staging and assessment of lymph node involvement with endoluminal US,CT,and MR imaging-a meta-analysis[J].Radiology,2004,232(3): 773-783.
[9]
Taylor FG, Quirke P, Heald RJ,et al.One millimeter is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer[J].Br J Surg,2011, 98(6): 872-879.
[10]
Smith NJ, Barbachano Y, Norman AR,et al.Prognostic significance of magnetic resonance imagingdetected extramural vascular invasion in rectal cancer[J].Br J Surg,2008, 95(2): 229-236.
[11]
Barbaro B, Fiorucci C, Tebala C,et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy[J].Radiology, 2009,250(3): 730-839.
[12]
Hanly AM, Ryan EM, Rogers AC,et al.Multicenter Evaluation of Rectal cancer ReImaging post Neoadjuvant (MERRION) Therapy[J]. Ann Surg, 2014, 259(4): 723.
[13]
肖晓娟,余深平,李子平,等.MR灌注成像在结直肠癌中的应用现状[J].国际医学放射学杂志,2015,(2): 138-142.
[14]
Kim SH, Lee JM, Hong SH,et al.Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy[J]. Radiology,2009,253(1): 116-125.
[15]
Wu LM, Zhu J, Hu J,et al.Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer? [J].Int J Colorectal Dis,2013,28(9): 1225-1238.
[16]
Heye T, Kuntz C, Düx M,et al.CT and endoscopic ultrasound in comparison to endoluminal MRI: preliminary results in staging gastric carcinoma[J].Eur J Radiol,2009,70(2): 336-341.
[17]
Zlobec I.Assessing downgrading of locally advanced rectal cancer after chemo-radiotherapy[J].Eur J Cancer, 2011,47(8): 1125-1126.
[18]
Ryan R, Gibbons D, Hyland J M P,et al.Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Histopathology, 2005, 47(2): 141-146.
[19]
Dede K, Salamon F, Landherr L,et al.Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?[J]. Pathol Oncol Res,2015, 21(1): 173-179.
[20]
Tie J, Kinde I, Wang Y,et al.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer[J]. Ann Oncol,2015,26(8): 1715-1722.
[21]
Bettegowda C, Sausen M, Leary RJ,et al.Detection of circulating tumor DNA in early- and late-stage human malignancies[J].Sci Transl Med,2014,6(224): 224ra24.
[22]
Magni E, Botteri E, Ravenda P S,et al.Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery[J].Int J Colorectal Dis,2014, 29(9): 1053-1059.
[23]
Han HJ, Russo J, Kohwi Y,et al. SATC reprogrammes gene expression to promote breast tumour growth and metastasis[J].Nature,2008,452(7184): 187-193.
[24]
Lu X, Cheng C, Zhu S,et al. SATC is an independent prognostic marker for gastric cancer in a Chinese population[J]. Oncol Rep,2010,24(4): 981-987.
[25]
Cheng C, Lu X, Wang G,et al.Expression of SATC and heparanase in gastric cancer and its relationship to clinicopathologic features[J]. APMIS,2010,118(11): 855-863.
[26]
Tu W, Luo M, Wang Z,et al.Upregulation of SATC promotes tumor growth and metastasis in liver cancer[J]. Liver Int, 2012,32(7): 1064-1078.
[27]
Meng WJ, Pathak S, Ding ZY, et al.Special AT-rich sequence binding protein 1 expression correlates with response to preoperative radiotherapy and clinical outcome in rectal cancer[J].Cancer Biol Ther,2015, 16(12): 1738-1745.
[28]
Sargent DJ, Marsoni S, Monges G,et al.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol,2010,28(20): 3219-3226.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 袁庆港, 刘理想, 张亮, 周世振, 高波, 丁超, 管文贤. 尿素-肌酐比值(UCR)可预测结直肠癌患者术后的长期预后[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 506-509.
[3] 高建新, 王啸飞, 于淼, 路夷平. 局部进展期直肠癌新辅助治疗后行ISR术远切缘距离的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 539-543.
[4] 李阳, 董峰, 曾立鹏. 局部进展期直肠癌新辅助治疗后腹腔镜TaTME与TME中的对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 547-550.
[5] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[6] 刘一鸣, 温佳新, 赵恺, 薛志强. ⅢA 期肺腺癌新辅助治疗后胸腔镜右肺中下叶切除术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 311-313.
[7] 周倜, 吴嘉, 韩方, 徐林伟, 张宇华. 新辅助治疗时代胰腺癌淋巴结清扫研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 634-639.
[8] 赵泽云, 李建男, 王旻. 中性粒细胞胞外诱捕网在结直肠癌中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 524-528.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 王国强, 张纲, 唐建坡, 张玉国, 杨永江. LINC00839 调节miR-17-5p/WEE1 轴对结直肠癌细胞增殖、凋亡和迁移的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 491-499.
[11] 孙晗, 于冰, 武侠, 周熙朗. 基于循环肿瘤DNA 甲基化的结直肠癌筛查预测模型的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 500-506.
[12] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13] 王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?